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Introduction
Arthritis is a complex disease with an unknown etiology.
Some of the common underlining symptoms include
inflammation, dysfunction of joints due to destruction of
cartilage and soft tissue. Based on the clinical symptoms,
arthritis can be classified as osteoarthritis (OA), rheuma-
toid arthritis, synovial lipomatosis, avascular necrosis,
crystal deposition disease, Goud and other diseases [1].
A major challenge we face in the postgenomic era is the
characterization of genes involved in oligogenic and poly-
genic disorders such as arthritis. This is because, unlike
monogenic diseases, pedigrees from complex diseases
reveal no Mendelian inheritance patterns, and gene muta-
tions are neither sufficient nor necessary to explain the
disease phenotypes.
Arthritis is a disease with complex traits influenced by
various risk factors. Multiple genetic, environmental and
epistatic determinants represent the greatest challenge for
genetic analysis, largely due to the difficulty of isolating the
phenotype of one gene amid the noise of other genetic
and environmental influences. It may be recognized that
the complexity is hidden in idealized laboratory settings
and in normal operations, but this complexity becomes
conspicuous when one notices a rare cascading failure,
primarily due to paradoxical features that keep together
the robustness, modularity, feedback, repair and fragility of
the complex biological system in arthritis.
The knowledge of new genomic information and the tools
to decipher it obviates the necessity to reassess our
working hypothesis. The ‘genomic tools’ will, for the first
time, allow us to analyze small amounts of surgical
samples (such as needle biopsies) and to analyze clinical
samples or cells (yielding 10–100pg nucleic acids) in the
context of the whole genome.
Preliminary genomic analysis in OA has already resur-
rected the debate on OA or osteoarthrosis based on the
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Abstract
‘Genomic tools’, such as gene/protein chips, single nucleotide polymorphism and haplotype analyses,
are empowering us to generate staggering amounts of correlative data, from human/animal genetics
and from normal and disease-affected tissues obtained from complex diseases such as arthritis. These
tools are transforming molecular biology into a ‘data rich’ science, with subjects with an ‘-omic’ suffix.
These disciplines have to converge and integrate at a systemic level to examine the structure and
dynamics of cellular and organismal function (‘functionomics’) simultaneously, using a multi-
dimensional approach for cells, tissues, organs, rodents and Zebra fish models, which intertwines
various approaches and readouts to study the development and homeostasis of a system. In summary,
the postgenomic era of functionomics will facilitate narrowing the bridge between correlative data and
causative data, thus integrating ‘intercoms’ of interacting and interdependent disciplines and forming a
unified whole.
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semantic issues in the definition of inflammation in carti-
lage in the postgenomic era of molecular medicine [2,3].
This has challenged a 20-century-old definition of inflam-
mation proposed by Cornelius Celsius. He defined inflam-
mation (redness and swelling with heat and pain [rubor et
tumor cum calore et dolor]) as an entity using a singular
rather than a plural noun, implying that it might be a single
process or a type of process. The avascular, alymphatic
and aneural human OA-affected articular cartilage harbor-
ing chondrocytes (like activated macrophages, but not
normal chondrocytes) shows superinduction of inflamma-
tory mediators as observed by gene chip analysis, but fails
to show the cardinal signs of inflammation [3]. These
types of analyses will not only facilitate development of
unbiased hypotheses at the molecular level, but will also
assist us in following the scent to the identification and
characterization of novel targets and disease markers for
pharmacological intervention, gene therapy and diagnosis.
A system approach to arthritis
‘General System Theory’, proposed in 1940, has per-
vaded all fields of science and has penetrated into popular
thinking in psychology, economics and social sciences.
The postgenomic revolution has redefined ‘System
Biology’ or ‘Whole-istic Biology’ [4,5]. Unraveling the
genetics of human diseases such as arthritis will require
moving beyond the focus on one gene at a time to explor-
ing pleiotropism, epistasis and environmental dependency
of genetic effects by integrating various technologies and
datasets forming a unified whole. There is consensus
among various investigators that a single genetic
approach is not sufficient to give a comprehensive analy-
sis of a complex disease, but rather would require an
entire arsenal of approaches as recently described by
Amin and coworkers [5,6].
A strategy for genomic analysis in arthritis
Reliable analysis of complex human diseases such as
arthritis will require graspable knowledge of the functional
interactions between key components of cells (such as
T cells, macrophages, neutrophils, osteoclasts, chondro-
cytes and synovial cells), tissues (synovium, bone and car-
tilage) and systems (mobile joints in animal models such
as rodents and Zebra fish), as well as the interactions that
change in the disease state (clinical material and diagno-
sis) (Fig.1). This information resides neither in the genome
nor in individual gene(s)/protein(s), but it seems to lie at
the level of protein interactions within the context of sub-
cellular, cellular, tissue, organ and system structure.
A system biology approach to functional genomics in
arthritis is shown in Fig.1. The scheme shows the role and
involvement of various cell types, tissues and organs, and
the use of animal models to understand the pathophysiol-
ogy of arthritis. Understanding expression and functions of
‘uncharacterized genes’ in target cells and various (normal
and disease) tissues requires the use of different cell
types in the complex interaction and interplay. The syn-
ovium can be classified and analyzed as normal and hyper-
trophic, and the latter can be subdivided as cartilage
invasive and noninvasive in different forms of arthritis [7].
The subchondral bone has been impacted significantly in
these diseases, as observed by the remodeling and thick-
ening in OA. The combined role of all five cell types
(T cells, macrophages, neutrophils, osteoclasts and chon-
drocytes) is important to understand the pathogenesis of
arthritis [8]. They may be acting as complex traits fine
tuning the disease process.
Mouse and Zebra fish models (knockin/knockout) have
been proven to mimic symptoms observed in man, as
shown for type II collagen and endothelin, respectively
[9,10]. For example, endothelin and its receptor were
found to be differentially expressed in normal and human
OA-affected cartilage (Amin, Attur and Dave, unpublished
data, 2003). A mutation of sucker that encodes a Zebra
fish endothelin 1 showed distortion of the ventral cartilage,
the pharyngeal segments and craniofacial development in
endothelin receptor-deficient mice [10,11]. Functional
genomics requires an integrated team of experts including
biochemists, cell biologists, structural biologists, physiolo-
gists and geneticists to create a unified whole due to the
unknown nature of genes to be analyzed and the type of
expertise regained. The structure–function relationship of
differentially expressed genes in normal and diseased
tissue can be analyzed in cells to organ cultures, as
recently described for a type II IL-1β decoy receptor [12].
At least four technologies have been extensively used for
gene mining and functional genomics. Figure 1 also
shows various approaches that can be applied selectively
or simultaneously to various cell types, organs, and animal
models and human subjects to understand the
structure–function relationship of genes in arthritis. These
include gene expression arrays, real-time PCR, proteo-
mics, high-throughput DNA sequencing, single nucleotide
polymorphism and haplotyping analysis, and 2D-matrix
assisted laser desorption ionization-time of flight (2D
MALD-TOF) [13,14].
Gene and protein mining technologies such as gene
expression array, proteomics, single nucleotide polymor-
phism, haplotyping and linkage disequilibrium, and
microsatellites generate a significant amount of correlative
data that requires annotating using various bioinformatic
platforms. Although computer-intensive disciplines and
bioinformatics allow clustering analysis for gene expres-
sion arrays and provide insight into the ‘correlation’ among
genes and biological phenomena, they have limitations in
revealing the ‘causality’ of regulatory relationships and/or
predicting  ab initio gene structure, gene function and
protein folds from the raw sequence data.78
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The key to bioinformatics is integration, interpretability
between various data platforms and the ability to visualize
retrieved complex data in a way that aids their interpreta-
tion. Integrating various incompatible bioinformatics plat-
forms is essential. Such efforts are currently under way by
the Interoperable Informatics Infrastructure Consortium, a
computer hardware 14-member organization. In summary,
bioinformatics facilitates deriving hypotheses allowing us
to enter the network structure, followed by identifying
structure–function relationships using other tools.
Functional genomics
Genomics has provided us with a massive ‘parts catalog’
for the human body in normal and disease states. Pro-
teomics seems to define some of these individual ‘parts’
and the structures they form in detail. There is no ‘user’s
guide’ describing how these parts are put together to
allow these interactions that sustain life or cause diseases.
However, the new emerging field of functional genomics
will provide such information.
Functional genomic analysis involves a systematic effort to
understand the function of genes and gene products (tran-
scripts and proteins) and their role in biological systems
(cells, tissues and organisms), until now classically per-
formed for single genes (e.g. generation of mutants, analy-
sis of proteins and transcripts), in the context of the whole
genome. While an understanding of genes and proteins
continues to be important, the focus should be on ascer-
taining a system’s structure and its dynamics.
Inspecting genome databases and expression arrays (of
an enzyme, transporter, receptor or ligand) without their
integrative functional knowledge with respect to various
Figure 1
An integrative system biology approach to functional genomics in arthritis. 2D-MALDI-TOFF, 2D-matrix assisted laser desorption ionizartion-time of
flight; OA, osteoarthritis; RA, rheumatoid arthritis; PCR, polymerase chain reaction; Wt, Wild type.79
forms of arthritis will be a starting point for functional
genomics in this area. These include a gene-driven
approach and a phenotype-driven approach. Both strate-
gies are complimentary, leading collectively to association
of the phenotype with genotypes, as recently reported
[5,6].
Conclusions and future directions
Functional genomics will begin to mature in the coming
decade into a coherent science (as molecular biology did
in the last half of the previous century), and its constituent
fields will become clearer. It is likely to give a whole new
meaning to clinical and genomic-based translational
research and biomarkers of over 35,000 possible data
points. The potential for its applications are infinite. The
present climate faces several challenges for those
attempting to perform genomic research on human sub-
jects, including informed consent, public acceptance,
sample collection and storage, and current technological
capabilities and cost. Among the several subcategories of
genomics, functional genomics is most closely linked to
pharmacogenomics. This has generated hype and hope
for a continuous metamorphosis of molecular medicine,
individualized drug therapy and pharmaceutical drug
development.
A lot clearly needs to be done as more than 40% of the
35,000 genes (and possibly 120,000 different proteins
they may code) have not been ascribed any functional
attribute [15], neither a biochemical function (e.g. kinase),
a cellular function (e.g. a specific signaling pathway) or a
function at the tissue/organism level (e.g. synovial hyper-
trophy, cartilage homeostasis, etc.). There is presently a
significant amount of ‘data dumping’ generated by arrays
and automation that does not make much sense. To
explore such a vast genome space, new technologies that
exploit and link genome and clinical data to ask entirely
new kinds of questions about the complex nature of arthri-
tis will be essential. Modern biologists, both accomplished
professionals and students, are unfortunately ill-prepared
for this changing role because of the understandable bias
in their background towards experimental techniques and
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